ClinicalTrials.gg
RecruitingNCT06934057CABOLDUpdated Sep 24, 2025

Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

A Phase 4 interventional study of Nivolumab and Cabozantinib in Kidney Cancer and Renal Cell Cancer, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 7 sites in France. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Primary conditionCarcinoma, Renal CellRegistry: Kidney NeoplasmsReclassifiedWhy we changed it
Registry
Kidney Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Renal Cell
Why
  1. The study's listed conditions name Carcinoma, Renal Cell, a narrower term within Kidney Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Phase 4, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies testing nivolumab in Carcinoma, Renal Cell — 9 open to participants now, 23 under way, 3 of them phase 3. Nivolumab · Carcinoma, Renal Cell.

Planned enrollment
33rd of 64
50 · median 52
Started
2025
with 1 other
Phase 4
4 of 64
2 open now
Primary completion
2028-04
later than 16 of 22 live
Registered
60th of 64
by date
Lead sponsor
2 of 64
Gustave Roussy, Cancer Campus, Grand Paris

Among the 64 studies testing nivolumab in Carcinoma, Renal Cell, this one is the 33rd largest by planned enrollment, is one of 2 that started in 2025, is one of 4 in phase 4, reaches primary completion later than 16 of the 22 other live ones, and was the 60th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

9 of the 64 studies testing nivolumab in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing nivolumab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer

Read the detailed description

This study will be a prospective, multicentric, single-arm cohort. Patients will receive Nivolumab-Cabozantinib association per standard. All patients will benefit of geriatric evaluation (G-CODE) at inclusion, and a multimodal and reinforced follow-up, including medical oncologist, geriatrician nurse of doctor, phone calls, and optional pharmacological follow-up for Cabozantinib.

03

Conditions studied

  • Kidney Cancer
  • Renal Cell Cancer

Browse trials for

Keywords

  • renal cell carcinoma
  • kidney cancer
  • cabozantinib
  • nivolumab
  • elderly patients
  • geriatric population
04

In context

Carcinoma, Renal Cell Reclassified

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

This study's planned enrollment of 50 is above the median of 43 across 1,569 interventional studies indexed under Carcinoma, Renal Cell.

Browse Carcinoma, Renal Cell studies →

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris is the lead sponsor of 245 studies on the registry; 66 are open to participants now.

Compared within Carcinoma, Renal Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Kidney Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥ 70 years-old
  2. Confirmed advanced or renal-cell carcinoma
  3. Patients not previously treated in metastatic setting
  4. Performance Status 0 to 2
  5. Sexually active male patients must agree to use condom during the study and for at least 5 months after the last study treatment administration. Also, it is recommended their women of partner use a highly effective method of .
  6. Patient should understand, sign, and date the written form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
  7. Patients must be affiliated to a social security system or beneficiary of the same

Exclusion criteria

Exclusion Criteria:

  1. Participation in another clinical study with an product during the last four weeks and while on study treatment (Patients may be included in CABOLD if they are included in the arm B of CARE1 study EUCT N° 2023-503317-29-00)
  2. Performance Status > 2
  3. Any condition that represent a to Cabozantinib and/or Nivolumab, as described in summaries of products characteristics, including symptomatic untreated or active auto-immune disease requiring systemic /modulator (thyroid or adrenal disorder are not an exclusion criteria)
  4. Any severe cardiovascular or thrombo-embolic event in the last three months
  5. Any situation for which exclusive palliative care intervention is recommended
  6. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Cabozantinib-Nivolumab

    The patient will be treated according to standard of care Nivolumab Cabozantinib.

    Drug: Nivolumab · Drug: Cabozantinib

Interventions

  • Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion.

    Also known as: OPDIVO

  • Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.

    Also known as: CABOMETYX

07

What researchers measure

Primary outcomes

  1. Starting dose of Cabozantinib

    Primary outcome measure is treatment patterns, which includes starting dose of cabozantinib.

    Time frame: 24 weeks after treatment start

  2. Dose interruption of Cabozantinib

    Primary outcome measure is treatment patterns of Cabozantinib, which includes the proportion of patients who experience any temporary dose interruption within the first 24 weeks of treatment.

    Time frame: 24 weeks after treatment start

  3. Dose modifications of Cabozantinib

    Primary outcome measure is treatment patterns, which includes the proportion of patients who experience any form of dose modification of Cabozantinib related to all grade toxicity within the first 24 weeks of treatment.

    Time frame: 24 weeks after treatment start

Secondary outcomes

  1. Overall response rate based on radiological evaluation

    Overall response rate based on best radiological response rate with local RECIST 1.1 evaluation observed in the 12 months of the study

    Time frame: 12 months after treatment start

  2. Overall-survival

    Defined as the time between the date of inclusion and the date of death whatever the cause. Patients alive at the date of last follow-up visit will be censored at that date.

    Time frame: 12 months after treatment start

  3. Progression free survival

    Progression free survival, defined by the time between inclusion date and the date of observation of a progression of the disease according to RECIST 1.1 or death of the patient (all causes combined) or date of last follow-up if the patient is alive without progression or lost to follow up.

    Time frame: 12 months after treatment start

  4. Duration of response

    It is defined as the time from first radiological evidence of response (partial or complete response) to disease progression or death among patients who achieve complete or partial response.

    Time frame: 12 months after treatment start

  5. Frequency of adverse events according to CTCAE V5

    Tolerance is evaluated based on physicians reports.

    Time frame: 12 months after treatment start

  6. Frequency of adverse events according to PRO-CTCAE

    Tolerance is evaluated based on patients reports.

    Time frame: 12 months after treatment start

  7. Quality of life - Patient-related outcomes - FACT-G

    Patients reported quality of life is evaluated based on Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire. It is an 27 item questionnaire, ranging from 0 to 108 score. Higher scores indicate better quality of life

    Time frame: At baseline, and every 3 months after treatment start, up to 12 months after treatment start

  8. Quality of life - Patient-related outcomes - FACIT TS-G

    Patients reported quality of life is evaluated based on Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT TS-G) questionnaire. The score range goes from 0 to 70 score. Higher scores indicate greater satisfaction with treatment

    Time frame: Every 3 months after treatment start, up to 12 months after treatment start

08

Study locations

1 of 7 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Apr 2028, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 18, 2025
StartActual
May 16, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06934057
Collaborators
Ipsen
Responsible party
Sponsor
First posted
Apr 18, 2025
Start date
May 16, 2025
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Sep 24, 2025

Study contacts

Maxime Frelaut, MD
Contact
Maxime.FRELAUT@gustaveroussy.fr
+33 1 42 11 57 60
Maia Claveau CLAVEAU
Contact
maia.claveau@gustaveroussy.fr
+33 1 42 11 53 49
Maxime FRELAUT, MD
principal investigator · Gustave Roussy, Cancer Campus, Grand Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Cabozantinib

Start the discussion